Conference Track

Lipodystrophy and Adverse Effects of Therapy

Source: CCO Independent Conference Coverage of the 2003 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Expert Analysis

Lipodystrophy & Adverse Effects of Therapy

Program Director: John P. Phair, MD

Faculty:

Judith S. Currier, MD, MSc
Donald P. Kotler, MD
William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss current insights into the pathogenesis and management of lipoatrophy
Review the relationships between lipid changes and HIV infection itself, antiretroviral therapy in general, and specific antiretroviral agents
Summarize recent data on the epidemiology and risk factors of cardiovascular disease in HIV-infected patients

Earn CME credit by reading the expert analysis and commentary on the antiretroviral management of patients receiving therapy. Topics covered include:

The D:A:D study
Carotid intima media thickness in HIV-infected patients
Evolution of lipid changes in MACS
Lipid effects of specific antiretrovirals
Studies of antiretrovirals in HIV-negative volunteers
Defining lipodystrophy: Data from FRAM and WIHS
Mechanisms of lipoatrophy
Reconstructive interventions for lipoatrophy
Osteopenia and osteoporosis

CREDIT INFORMATION

Release Date: March 12, 2003

Expiration Date: March 11, 2004

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.